U.S. flag

An official website of the United States government

NM_000152.5(GAA):c.-2C>T AND not specified

Germline classification:
Benign/Likely benign (2 submissions)
Last evaluated:
Jul 30, 2020
Review status:
2 stars out of maximum of 4 stars
criteria provided, multiple submitters, no conflicts
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV000352150.6

Allele description [Variation Report for NM_000152.5(GAA):c.-2C>T]

NM_000152.5(GAA):c.-2C>T

Gene:
GAA:alpha glucosidase [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
17q25.3
Genomic location:
Preferred name:
NM_000152.5(GAA):c.-2C>T
HGVS:
  • NC_000017.11:g.80104585C>T
  • NG_009822.1:g.8030C>T
  • NM_000152.5:c.-2C>TMANE SELECT
  • NM_001079803.3:c.-2C>T
  • NM_001079804.3:c.-2C>T
  • NM_001406741.1:c.-2C>T
  • NM_001406742.1:c.-2C>T
  • LRG_673t1:c.-2C>T
  • LRG_673:g.8030C>T
  • NC_000017.10:g.78078384C>T
  • NM_000152.3:c.-2C>T
  • NM_000152.4:c.-2C>T
Links:
dbSNP: rs560511228
NCBI 1000 Genomes Browser:
rs560511228
Molecular consequence:
  • NM_000152.5:c.-2C>T - 5 prime UTR variant - [Sequence Ontology: SO:0001623]
  • NM_001079803.3:c.-2C>T - 5 prime UTR variant - [Sequence Ontology: SO:0001623]
  • NM_001079804.3:c.-2C>T - 5 prime UTR variant - [Sequence Ontology: SO:0001623]
  • NM_001406741.1:c.-2C>T - 5 prime UTR variant - [Sequence Ontology: SO:0001623]
  • NM_001406742.1:c.-2C>T - 5 prime UTR variant - [Sequence Ontology: SO:0001623]
Observations:
1

Condition(s)

Synonyms:
AllHighlyPenetrant
Identifiers:
MedGen: CN169374

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV000335646Eurofins Ntd Llc (ga)
criteria provided, single submitter

(EGL Classification Definitions 2015)
Likely benign
(Oct 7, 2015)
germlineclinical testing

Citation Link,

SCV001426891Women's Health and Genetics/Laboratory Corporation of America, LabCorp
criteria provided, single submitter

(LabCorp Variant Classification Summary - May 2015)
Benign
(Jul 30, 2020)
germlineclinical testing

Citation Link

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknown1not providednot providednot providednot providedclinical testing

Details of each submission

From Eurofins Ntd Llc (ga), SCV000335646.4

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not provided1not providednot providedclinical testingnot provided
#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot provided1not providednot providednot provided

From Women's Health and Genetics/Laboratory Corporation of America, LabCorp, SCV001426891.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testingnot provided

Description

Variant summary: GAA c.-2C>T is located in the untranslated mRNA region upstream of the initiation codon. 4/4 computational tools predict no significant impact on normal splicing. However, these predictions have yet to be confirmed by functional studies. The variant allele was found at a frequency of 0.001 in 247028 control chromosomes, predominantly at a frequency of 0.008 within the South Asian subpopulation in the gnomAD database, including 5 homozygotes. The observed variant frequency within South Asian control individuals in the gnomAD database is approximately 2-fold of the estimated maximal expected allele frequency for a pathogenic variant in GAA causing Glycogen Storage Disease, Type 2 (Pompe Disease) phenotype (0.0042), strongly suggesting that the variant is a benign polymorphism found primarily in populations of South Asian origin. To our knowledge, no occurrence of c.-2C>T in individuals affected with Glycogen Storage Disease, Type 2 (Pompe Disease) and no experimental evidence demonstrating its impact on protein function have been reported. Two clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation, and both of them classified the variant as likely benign. Based on the evidence outlined above, the variant was classified as benign.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Dec 24, 2023